Elaine Rufo Tavares

Elaine Rufo Tavares

Auto-generated profile, based on publicly available information

Elaine Rufo Tavares

Universidade de São Paulo, Brasil

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2008 in Atherosclerosis
Verified
Journal Article
Closed access
RMRaul Cavalcante Maranhao
Raul Cavalcante Maranhao
ETElaine R. Tavares
Elaine R. Tavares
APAmanda F. Padoveze
Amanda F. Padoveze
CVClaudete J. Valduga
Claudete J. Valduga
DRDebora G. Rodrigues
Debora G. Rodrigues
MPMaria D. Pereira
Maria D. Pereira

1 June 2012 in Brazilian Journal of Medical and Biological Research
Verified
Journal Article
Open access
PDF file
LPL.A. Pires
L.A. Pires
RHR. Hegg
R. Hegg
FFFatima Rodrigues Freitas
Fatima Rodrigues Freitas
ETE.R. Tavares
E.R. Tavares
CAC.P. Almeida
C.P. Almeida
RMRaul Cavalcante Maranhao
Raul Cavalcante Maranhao
Low-density lipoprotein (LDL) receptors are overexpressed in most neoplastic cell lines and provide a mechanism for the internalization and concentration of drug-laden nanoemulsions that bind to these receptors. The aim of the present study was to determine whether the administration of standard chemotherapeutic schemes can alter the expression of LDL and LDL receptor-related protein 1 (LRP-1) receptors in breast carcinoma. Fragments of tumoral and normal breast tissue from 16 consecutive volunteer women with breast cancer in stage II or III were obtained from biopsies before the beginning of neoadjuvant chemotherapy and after chemotherapy, from fragments excised during mastectomy. Tissues were analyzed by immunohistochemistry for both receptors. Because complete response to treatment was achieved in 4 patients, only the tumors from 12 were analyzed. Before chemotherapy, there was overexpression of LDL receptor in the tumoral tissue compared to normal breast tissue in 8 of these patients. LRP-1 receptor overexpression was observed in tumors of 4 patients. After chemotherapy, expression of both receptors decreased in the tumors of 6 patients, increased in 4 and was unchanged in 2. Nonetheless, even when chemotherapy reduced receptors expression, the expression was still above normal. The fact that chemotherapy does not impair LDL receptors expression supports the use of drug carrier systems that target neoplastic cells by the LDL receptor endocytic pathway in patients on conventional chemotherapy.

1 May 2017 in International Journal of Nanomedicine
Verified
Journal Article
Open access
PDF file
RMRaul Cavalcante Maranhao
Raul Cavalcante Maranhao
MGMaria Carolina Guido
Maria Carolina Guido
Aline Derisio de LimaAline Derisio de Lima
Aline Derisio de Lima
ETElaine Rufo Tavares
Elaine Rufo Tavares
AMAlyne Franca Marques
Alyne Franca Marques
RKRoberto Kalil-Filho
Roberto Kalil-Filho
Purpose: Acute myocardial infarction (MI) is accompanied by myocardial inflammation, fibrosis, and ventricular remodeling that, when excessive or not properly regulated, may lead to heart failure. Previously, lipid core nanoparticles (LDE) used as carriers of the anti-inflammatory drug methotrexate (MTX) produced an 80-fold increase in the cell uptake of MTX. LDE-MTX treatment reduced vessel inflammation and atheromatous lesions induced in rabbits by cholesterol feeding. The aim of the study was to investigate the effects of LDE-MTX on rats with MI, compared with commercial MTX treatment. Materials and methods: Thirty-eight Wistar rats underwent left coronary artery ligation and were treated with LDE-MTX, or with MTX (1 mg/kg intraperitoneally, once/week, starting 24 hours after surgery) or with LDE without drug (MI-controls). A sham-surgery group (n=12) was also included. Echocardiography was performed 24 hours and 6 weeks after surgery. The animals were euthanized and their hearts were analyzed for morphometry, protein expression, and confocal microscopy. Results: LDE-MTX treatment achieved a 40% improvement in left ventricular (LV) systolic function and reduced cardiac dilation and LV mass, as shown by echocardiography. LDE-MTX reduced the infarction size, myocyte hypertrophy and necrosis, number of inflammatory cells, and myocardial fibrosis, as shown by morphometric analysis. LDE-MTX increased antioxidant enzymes; decreased apoptosis, macrophages, reactive oxygen species production; and tissue hypoxia in non-infarcted myocardium. LDE-MTX increased adenosine bioavailability in the LV by increasing adenosine receptors and modulating adenosine catabolic enzymes. LDE-MTX increased the expression of myocardial vascular endothelium growth factor (VEGF) associated with adenosine release; this correlated not only with an increase in angiogenesis, but also with other parameters improved by LDE-MTX, suggesting that VEGF increase played an important role in the beneficial effects of LDE-MTX. Overall effects of commercial MTX were minor, and did not improve LV function or infarction size. Both treatments did not induce any toxicity. Conclusion: The remarkable improvement in heart function and reduction in infarction size achieved by LDE-MTX supports future clinical trials.

20 May 2018 in Journal of Cardiovascular Pharmacology and Therapeutics
Verified
Journal Article
Closed access
FGFernando L. T. Gomes
Fernando L. T. Gomes
RMRaul Cavalcante Maranhao
Raul Cavalcante Maranhao
ETElaine R. Tavares
Elaine R. Tavares
PCPriscila O. Carvalho
Priscila O. Carvalho
MHMaria de Lourdes Higuchi
Maria de Lourdes Higuchi
CSCarlos V. Serrano
Carlos V. Serrano
In previous studies, it was demonstrated that lipid core nanoparticles (LDE) resemble the low-density lipoprotein structure and carrying the antiproliferative agent paclitaxel (PTX) strongly reduced atherosclerosis lesions induced in rabbits by cholesterol feeding. Currently, the aim was to verify whether combining LDE-PTX treatment with methotrexate (MTX) associated with LDE (LDE-MTX) could accelerate the atherosclerosis regression attained with single LDE-PTX treatment, after withdrawing the cholesterol feeding. Thirty-eight rabbits were fed 1% cholesterol chow for 8 weeks. Six of these rabbits were then euthanized for analyses of the aorta (controls). In the remaining rabbits, cholesterol feeding was withdrawn, and those 32 animals were allocated to 3 groups submitted to different 8-week intravenous treatments, all once/week: LDE-PTX (n = 10; 4 mg/kg), LDE-PTX + LDE-MTX (n = 11; 4 mg/kg), and LDE-alone (n = 11). Rabbits were then euthanized and aortas were excised for morphometric, immunohistochemical, and gene expression analyses. After cholesterol feeding withdrawal, in comparison with LDE-alone group, both LDE-PTX and LDE-PTX + LDE-MTX treatments had the ability to increase the regression of plaque areas: −49% in LDE-PTX and −59% for LDE-PTX + LDE-MTX. However, only LDE-PTX + LDE-MTX treatment elicited reduction in the intima area, estimated in −57%. Macrophage presence in aortic lesions was reduced 48% by LDE-PTX and 43% by LDE-PTX + LDE-MTX treatment. Matrix metalloproteinase 9 was reduced by either LDE-PTX (74%) or LDE-PTX + LDE-MTX (78%). Tumor necrosis factor α gene expression was reduced 65% by LDE-PTX and 79% by LDE-PTX + LDE-MTX. In conclusion, treatment with LDE-PTX indeed accelerated plaque reduction after cholesterol feeding; LDE-PTX + LDE-MTX further increased this effect, without any observed toxicity. These results pave the way for the use of combined chemotherapy to achieve stronger effects on aggravated, highly inflamed atherosclerotic lesions.

16 December 2016 in Human Reproduction
Verified
Journal Article
Open access
PDF file
LGLuciano Gibran
Luciano Gibran
RMRaul C. Maranhão
Raul C. Maranhão
ETElaine R. Tavares
Elaine R. Tavares
PCPriscila O. Carvalho
Priscila O. Carvalho
MAMaurício S. Abrão
Maurício S. Abrão
SPSergio Podgaec
Sergio Podgaec
Is mRNA expression of LDL receptors altered in deep bowel endometriotic foci? mRNA expression of LDL receptors is up-regulated in deep bowel endometriotic foci of patients with endometriosis. Several studies have demonstrated the overexpression of low-density lipoprotein receptors in various tumour cell lines and endometriosis has similar aspects to cancer, mainly concerning the pathogenesis of both diseases. This is the first study we know of to investigate lipoprotein receptors expression in deep endometriosis with bowel involvement. During 2014–2015, an exploratory case-control study was conducted with 39 patients, including 20 women with a histological diagnosis of deep endometriosis compromising the bowel and 19 women without endometriosis who underwent laparoscopic tubal ligation. Peripheral blood samples were collected on the day of surgery for lipid profile analysis, and samples of endometrial tissue and of bowel endometriotic lesions were also collected. The tissue samples were sent for histopathological analysis and for LDL-R and LRP-1 gene expression screening using quantitative real-time PCR. Patients with deep endometriosis had lower LDL-cholesterol than patients without the disease (119 ± 23 versus 156 ± 35; P = 0.001). Gene expression analysis of LDL receptors revealed that LDL-R was more highly expressed in endometriotic lesions when compared to the endometrium of the same patient but not more than in the endometrium of women without endometriosis (0.027 ± 0.022 versus 0.012 ± 0.009 versus 0.019 ± 0.01, respectively; P < 0.001). LRP-1 was more highly expressed in endometriotic lesions, both when compared with the endometrium of the same patient and when compared with the endometrium of patients without the disease (0.307 ± 0.207 versus 0.089 ± 0.076 and versus 0.126 ± 0.072, respectively; P < 0.001). The study also showed that LDL-R gene expression in the endometrium of women with endometriosis was higher during the secretory phase of the menstrual cycle (P = 0.001). LRP-1 gene expression was increased during the secretory phase in the endometrium of women without the disease (P = 0.008). In the endometriotic lesions, the presence of fibrosis is substantial, restricting access to the stromal and glandular components of the lesion. Despite that, we found that LDL receptor mRNA was overexpressed. Future studies may perform laser microdissection to isolate the area of interest in the target tissue, excluding fibrosis contamination. This study supports the feasibility of LDL-R targeted therapy in the treatment of deep endometriosis. This study was supported by Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP #2011/17245-0). The authors have no conflicts of interest to declare.

1 October 2011 in International Journal of Nanomedicine
Verified
Journal Article
Open access
RMRaul Cavalcante Maranhao
Raul Cavalcante Maranhao
JMJuliana Moura
Juliana Moura
CVClaudete J Valduga
Claudete J Valduga
ETElaine R Tavares
Elaine R Tavares
MAMaria
Maria
DMDurvanei A Maria
Durvanei A Maria
Peer reviewed article authored by (Moura JA, Valduga CJ, Tavares ER, Kretzer IF, Maria DA, Maranhao RC). Read article or submit your manuscript for publishing.